Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.
Matico R, Grauwen K, Chauhan D, Yu X, Abdiaj I, Adhikary S, Adriaensen I, Aranzazu GM, Alcázar J, Bassi M, Brisse E, Cañellas S, Chaudhuri S, Delgado F, Diéguez-Vázquez A, Du Jardin M, Eastham V, Finley M, Jacobs T, Keustermans K, Kuhn R, Llaveria J, Leenaerts J, Linares ML, Martín ML, Martín-Pérez R, Martínez C, Miller R, Muñoz FM, Muratore ME, Nooyens A, Perez-Benito L, Perrier M, Pietrak B, Serré J, Sharma S, Somers M, Suarez J, Tresadern G, Trabanco AA, Van den Bulck D, Van Gool M, Van Hauwermeiren F, Varghese T, Vega JA, Youssef SA, Edwards MJ, Oehlrich D, Van Opdenbosch N.
Matico R, et al. Among authors: martin ml.
EMBO Mol Med. 2024 Dec 9. doi: 10.1038/s44321-024-00181-4. Online ahead of print.
EMBO Mol Med. 2024.
PMID: 39653810